A phase 1, first-in-human study of IK-930, an oral TEAD inhibitor targeting the Hippo pathway in subjects with advanced solid tumors

被引：0
|
作者：
Tolcher, Anthony W.
Lakhani, Nehal J.
McKean, Meredith
Lingaraj, Trupti
Victor, Laura
Sanchez-Martin, Marta
Kacena, Katherine
Malek, Karim S.
Santillana, Sergio
机构：
[1] NEXT Oncol & Texas Oncol, San Antonio, TX USA
[2] START Midwest, Grand Rapids, MI USA
[3] Sarah Cannon Res Inst, Tennessee Oncol, PLLC, Nashville, TN USA
[4] Ikena Oncol, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3168
引用
收藏
页数：1
相关论文
共 50 条
  • [41] First-in-human study with ARQ 092, a novel pan AKT-inhibitor, in subjects with advanced solid tumors or recurrent malignant lymphoma
    Saleh, M.
    Papadpoulos, K.
    Arabnia, A.
    Patnaik, A.
    Stein, R. M.
    Chai, F.
    Lamar, M.
    Savage, R.
    Abbadessa, G.
    Tolcher, A.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 104 - 104
  • [42] First-in-human phase 1 dose escalation study of the KAT6 inhibitor PF-07248144 in patients with advanced solid tumors
    Sommerhalder, David
    Hamilton, Erika P.
    Mukohara, Toru
    Yonemori, Kan
    Mita, Monica M.
    Yamashita, Toshinari
    Zheng, Jenny
    Liu, Li
    Maity, Arnab K.
    Mishra, Natasha Homji
    Bogg, Orlaith
    Li, Meng
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [43] A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors
    Lee S. Rosen
    Patricia LoRusso
    Wen Wee Ma
    Jonathan W. Goldman
    Amy Weise
    A. Dimitrios Colevas
    Alex Adjei
    Salim Yazji
    Angela Shen
    Stuart Johnston
    Hsin-Ju Hsieh
    Iris T. Chan
    Branimir I. Sikic
    Investigational New Drugs, 2016, 34 : 604 - 613
  • [44] Phase I/II first-in-human study of TT-10 (A2AB inhibitor) as a single agent in subjects with advanced selected solid tumors
    Kumar, Sushant
    Mookhtiar, Kasim
    Pastore, Desa Rae
    Schwartz, Brian
    Reddy, Vijay
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [45] A first-in-human phase I study to evaluate the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors
    Varga, A.
    Soria, J. C.
    Hollebecque, A.
    LoRusso, P.
    Vaishampayan, U.
    Okrah, K.
    Huang, S. M. A.
    Murray, E.
    Sanabria-Bohorquez, S.
    Tagen, M.
    Dokainish, H.
    Mueller, L.
    Burris, H.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S11 - S11
  • [46] A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
    Varga, Andrea
    Soria, Jean-Charles
    Hollebecque, Antoine
    LoRusso, Patricia
    Bendell, Johanna
    Huang, Shih-Min A.
    Wagle, Marie-Claire
    Okrah, Kwame
    Liu, Lichuan
    Murray, Elaine
    Sanabria-Bohorquez, Sandra M.
    Tagen, Michael
    Dokainish, Hatem
    Mueller, Lars
    Burris, Howard
    CLINICAL CANCER RESEARCH, 2020, 26 (06) : 1229 - 1236
  • [47] A first-in-human phase 1 study of a novel PARP7 inhibitor RBN-2397 in patients with advanced solid tumors.
    Falchook, Gerald Steven
    Patel, Manish R.
    Yap, Timothy A.
    McEachern, Kristen
    Kuplast-Barr, Kristy
    Utley, Luke
    Cleary, Lisa
    Manyak, Erika
    Bozon, Viviana
    Parasuraman, Sudha
    Johnson, Melissa Lynne
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [48] A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors
    Rosen, Lee S.
    LoRusso, Patricia
    Ma, Wen Wee
    Goldman, Jonathan W.
    Weise, Amy
    Colevas, A. Dimitrios
    Adjei, Alex
    Yazji, Salim
    Shen, Angela
    Johnston, Stuart
    Hsieh, Hsin-Ju
    Chan, Iris T.
    Sikic, Branimir I.
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (05) : 604 - 613
  • [49] Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors
    Bahleda, R.
    Meric-Bernstam, F.
    Goyal, L.
    Tran, B.
    He, Y.
    Yamamiya, I
    Benhadji, K. A.
    Matos, I
    Arkenau, H-T
    ANNALS OF ONCOLOGY, 2020, 31 (10) : 1405 - 1412
  • [50] A first-in-human phase I study of the ATM inhibitor M4076 in patients with advanced solid tumors (DDRiver Solid Tumors 410): Part 1A results
    Siu, Lillian L.
    Yap, Timothy A.
    Genta, Sofia
    Pennock, Gregory
    Hicking, Christine
    You, Xiaoli
    Mukker, Jatinder K.
    Locatelli, Giuseppe
    Tolcher, Anthony W.
    CANCER RESEARCH, 2023, 83 (08)
12345